Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
US9034840B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9034840-B2 |
| Application number | US-201113994862-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 19, 2011 |
| Priority date | Dec 17, 2010 |
| Publication date | May 19, 2015 |
| Grant date | May 19, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating cancer comprising the step of administering an effective amount of a Translationally-Controlled Tumor Protein (TCTP) antagonist to an individual in need thereof, wherein said antagonist is a nucleic acid targeting a mRNA encoding TCTP, wherein said nucleic acid is capable of reducing the amount of TCTP in cells, and wherein said cancer is a hormone-independent cancer or chemo-resistant cancer. 2. The method of…
Assignees
Inventors
Classifications
- A61K31/7088Primary
Human Necessities · mapped topic
- A61K45/06Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9034840B2 cover?
- The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
- Who is the assignee on this patent?
- Rocchi Palma, Baylot Virginie, Acunzo Julie, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).